机译:小分子抑制剂对人类MDM2 N末端的排序
Molecular Structure & Characterization, Amgen, Inc., Thousand Oaks, California 91320, United States;
Molecular Structure & Characterization, Amgen, Inc., Thousand Oaks, California 91320, United States;
Protein Technology, Amgen. Inc., Thousand Oaks, California 91320, United States;
Molecular Structure & Characterization, Amgen, Inc., Cambridge, Massachusetts 02139, United States;
Protein Technology, Amgen. Inc., Thousand Oaks, California 91320, United States;
Department of Medicinal Chemistry, Amgen, Inc., South San Francisco, California 94080, United States;
Molecular Structure & Characterization, Amgen, Inc., South San Francisco, California 94080, United States;
Protein Technology, Amgen, Inc., Cambridge, Massachusetts 02139, United States;
Molecular Structure & Characterization, Amgen, Inc., Thousand Oaks, California 91320, United States;
Molecular Structure & Characterization, Amgen, Inc., Cambridge, Massachusetts 02139, United States;
Molecular Structure & Characterization, Amgen, Inc., Thousand Oaks, California 91320, United States;
机译:MDM2-p53蛋白-蛋白质相互作用的小分子抑制剂(MDM2抑制剂)在癌症治疗的临床试验中
机译:254邀请的人类MDM2-p53相互作用的小分子抑制剂作为抗癌药
机译:254邀请的人类MDM2-p53相互作用的小分子抑制剂作为抗癌药
机译:通过同源造型和分子对接的P53-MDM2蛋白复合物的抑制剂的硅筛选
机译:第一部分。设计用于人类颗粒酶B(hBrB)的新型可逆非共价小分子抑制剂。第二部分。姜黄素和模拟物作为蛋白酶体抑制剂第三部分。新型的针对雌激素受体α的共激活因子结合抑制剂(CBI)的设计:打破1μM的障碍。
机译:小分子抑制剂MDM2-p53蛋白-蛋白质的合成相互作用(MDM2抑制剂)在癌症治疗的临床试验中
机译:最近的P53-MDM2蛋白质 - 蛋白质相互作用的近期小分子抑制剂